Compass Pathways has stronger COMP360 data, but can psilocybin treatment scale?
Find out how Compass Pathways’ COMP360 Phase 3 data could shape regulated psilocybin treatment for depression.
Pharma & Biotech
Pharma & Biotech
Why HOPE Therapeutics’ first Zeta-guided TMS patients matter for psychiatry care
NRx’s HOPE Therapeutics begins Zeta-guided TMS treatments, bringing AI-powered image guidance into outpatient depression care workflows.
Pharma & Biotech
Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.
Pharma & Biotech
Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.
Pharma & Biotech
Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
Can Alto Neuroscience’s ALTO-207 change treatment-resistant depression care? Read what the new Phase 2b trial could mean for psychiatry.
Pharma & Biotech
What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia
Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.
Medical Devices & Diagnostics
FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?
Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.
Pharma & Biotech
Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development
Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.